Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Osteosarcoma × fluzoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 16 Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Sarcoma 3 Prostatic Neoplasms 3 Fallopian Tube Neoplasms 3 Solid Tumor 2 Recurrence 2 Neoplasms 2 Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Advanced Solid Tumors 2 Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 SCLC, Extensive Stage 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Kenny-Caffey syndrome, Type 1 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Female Breast Cancer Patients 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

Ifosfamide 27 Methotrexate 23 Doxorubicin 21 Cyclophosphamide 20 Cisplatin 19 Filgrastim 15 Etoposide 15 Gemcitabine 14 Leucovorin 12 Magnetic Resonance Spectroscopy 10 Temozolomide 9 Specimen Handling 9 Granulocyte Colony-Stimulating Factor 8 fludarabine 7 Zoledronic Acid 7 X-Rays 7 Sirolimus 7 Nivolumab 7 Neoadjuvant Therapy 7 Irinotecan 7 Docetaxel 7 Carboplatin 7 Biopsy 7 apatinib 6 Phantoms, Imaging 6 Mesna 6 cabozantinib 5 Vincristine 5 Topotecan 5 Radiotherapy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06074692 2023-10-31

PRIMA

Ruijin Hospital

Phase 2 Recruiting

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡